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Reviews show that using snus (Swedish-type moist snuff) is much safer than smoking, with no increased
risk from snus of cancer or circulatory disease yet demonstrated, but have not investigated possible
health effects from dual use of cigarettes and snus. This review considers studies where health risks
can be compared in dual users, those who only use snus or only smoke, and those who use neither prod-
uct. The interaction RR, the ratio of RRs associated with snus use in smokers and in non-smokers, was
used to test for special effects of dual use. Of 51 interaction RRs presented, only one (for gestational
hypertension in a study based on the Swedish Medical Register) was signiﬁcantly (p < 0.05) above 1.0,
and RRs below 1.0 were commoner, perhaps as cigarette consumption is lower in dual users than those
who only smoke. Dual users more often initiate tobacco use with cigarettes than snus. Dual use is much
commoner in adolescents than adults, possibly because many tobacco users try both products, eventually
settling on one. Epidemiological evidence from various sources, though suffering from weaknesses, con-
sistently suggests concomitant snus use increases smoking quit rates, and aligns with evidence from RCTs
using snus to aid smoking cessation.
 2013 The Author. Published by Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Swedish-type moist snuff (‘‘snus’’) consists of ﬁnely ground air-
or sun-cured tobacco, salt (sodium chloride), water, humidifying
agents, chemical buffering agents (sodium carbonate), and food-
grade ﬂavourings. The tobacco is often heat-treated (pasteurized).
In the past, a pinch (or dip) was placed between the gum and upper
lip, often for 11–14 h daily (International Agency for Research on
Cancer, 2007), but more recently the commonest application meth-
od is by portion-packed tobacco in a small sachet (similar to a tea-
bag). Although the sale of snus is banned in other EU countries,
Sweden has a special derogation due to its long history of use.
In the last decade, there has been increasing interest in snus as a
possible safer alternative to smoking. Various reviews (e.g. Boffetta
et al., 2008; Broadstock, 2007; Kallischnigg et al., 2008; Lee, 2007;
Lee and Hamling, 2009; Scientiﬁc Committee on Emerging andNewly Identiﬁed Health Risks (SCENIHR), 2008; Weitkunat et al.,
2007) have considered possible health effects, with oral and pan-
creatic cancer, oral disease, and cardiovascular disease (CVD)
receiving particular attention.
A recent summary, with meta-analyses, of the epidemiological
evidence relating snus to health (Lee, 2011) found no statistically
signiﬁcant association with cancer of any site or with heart disease
or stroke, and concluded that any possible risk from snus, if it ex-
ists, is much less than that from smoking. It also noted that ‘‘snuff
dipper’s lesion’’ (Axéll et al., 1976) does not predict oral cancer.
Though that summary considered a wide range of possible health
effects, and also found no reliable evidence that snus increases ini-
tiation of smoking or discourages quitting, it did not evaluate
health effects associated speciﬁcally with dual use of cigarettes
and snus.
In this systematic review, evidence directly relating dual use to
various health endpoints is of primary interest. However, other as-
pects of dual use are also investigated, including comparison of cig-
arette and snus consumption in single and dual users, and a
summary of data on the frequency of dual use and on various as-
pects of the interrelationship of snus use and smoking, such as
which tobacco product dual users tend to start with. Associated
with this, transitions to dual use and from dual use are considered,
to gain insight into whether snus use affects initiation or cessation
of smoking.
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2.1. Health effects
The searches concerned cancer, circulatory disease, respiratory
and digestive disease, all-cause mortality, pregnancy and repro-
ductive effects, psychiatric and neurodegenerative disorders, mus-
culoskeletal disorders and other conditions, and general health, all
these health effects being considered in the review of snus and
health (Lee, 2011). The publications on these health effects cited
in that review were considered, as well as additional publications
obtained by updating the literature search to February 2013, using
the same search criteria used in 2011. All these publications were
then examined to assess whether they presented results allowing
comparison of risk in those who smoked and used snus (‘‘dual
users’’), those who smoked but did not use snus (‘‘smoking only’’),
those who used snus but did not smoke (‘‘snus only’’), and those
who neither smoked nor used snus (‘‘neither’’). Smoking and snus
use could be based on current or on lifetime habits.
Comparisons were made separately for ever and never smokers,
of health risks for ever and never snus use, and separately for cur-
rent and non-current smokers of health risks for current and non-
current snus use. For each comparison, standard methods (Gardner
and Altman, 1989) were used to estimate the relative risk (RR) or
odds ratio (OR) and 95% conﬁdence interval (CI) for snus only vs.
neither, for dual use vs. smoking only, and for their interaction,
i.e. the ratio of these two RR/OR estimates. The interaction tests
whether the proportional increase in risk associated with snus is
greater in smokers than in non-smokers (or equivalently whether
the proportional increase in risk associated with smokers is greater
in snus users than that associated with smoking in non-users of
snus), i.e. whether there is any special hazard associated with dual
use.
Where, as is usually the situation, a study provides a set of
covariate-adjusted RR/ORs (with 95% CIs) for a complex two-way
table of smoking by snus use (e.g. never/current/former smok-
ing  never/current/former snus), the required RR/OR estimates
were derived from the set using standard methods (Hamling
et al., 2008). Only where covariate-adjusted RRs were not provided,
were unadjusted estimates calculated directly from the given num-
bers of cases and controls. In some cases the required RRs/ORs
were derived from estimates for ever snus use given separately
for never smokers and for the whole population.
Where appropriate, meta-analyses of estimates were derived
using standard methods (Fleiss and Gross, 1991).2.2. Other aspects of dual use
The aim was to gain insight into seven questions: (1) how does
the cigarette consumption of dual users compare to that of smok-
ers of cigarettes only? (2) How does the snus consumption of dual
users compare to that of users of snus only? (3) What is the fre-
quency of dual use? (4) Are current snus users more likely to
smoke than are current non-users of snus? (5) Are those who have
ever used snus more likely ever to have smoked than are never
users of snus? (6) Are snus users more likely to initiate smoking
than non-users? and (7) Are smokers who also use snus more likely
to quit smoking than smokers who do not use snus? Again, publi-
cations cited in the earlier review (Lee, 2011) were considered, as
well as additional publications from updated literature searches.
References cited in the recently updated Scandinavian chapters
of international smoking statistics (Forey et al., 2006–2013) were
also examined.
For cross-sectional studies relating snus to smoking, ORs (with
95% CIs) relevant to questions 4 and 5 were derived from thenumbers of subjects who were dual users, smoking only, snus only,
or neither. RRs (with 95% CIs) relevant to question 6 were derived
from cohort studies, using the numbers of non-smokers at baseline
and the numbers subsequently initiating, separated by snus use at
baseline. For cohort studies relating snus use at baseline to subse-
quent quitting, RRs (with 95% CIs) relevant to question 7 were also
derived from cohort studies, here using the numbers of smokers at
baseline and the numbers subsequently quitting. As many of the
results relating to questions 3–7 were presented earlier (Lee,
2011), only selected results are presented for more recent, larger
and more nationally representative surveys.3. Results
3.1. Health effects
The literature search identiﬁed 21 relevant publications for
which Table 1 presents study details. Four publications relate to
the Swedish construction workers study, three (Carlens et al.,
2010; Nordenvall et al., 2011; Zendehdel et al., 2008) concerning
occurrence of various conditions seen during the more than
20 years follow-up, the other (Nordenvall et al., 2013) concerning
survival among those with incident cancer seen after baseline. An-
other four publications (Gunnerbeck et al., 2011; Wikström et al.,
2010a,b,c) are based on the Swedish Medical Birth Register. The
remaining thirteen publications describe separate studies, four
prospective cohort studies, eight case-control studies (one nested
within a prospective study), and one cross-sectional study. All
the studies were conducted in Sweden, and apart from publica-
tions based on the Swedish Medical Birth Register, the snus users
considered were either all or virtually all men.
Table 2 summarizes results for cardiovascular disease, with the
main results presented in the body of the table and results for sub-
groups (e.g. for fatal and non-fatal cases separately) given in the
footnotes. Most of the results relate to current tobacco use. None
of the RR/ORs presented show a signiﬁcant (p < 0.05) increased risk
associated with snus use, either in non-smokers or smokers, or a
signiﬁcant interaction associated with dual use. Based on seven re-
sults for current use for ischaemic heart disease (IHD), coronary
heart disease (CHD) or acute myocardial infarction (AMI), meta-
analysis gives non-signiﬁcant estimates of 0.95 (0.83–1.09) for
snus only vs. neither, 0.82 (0.67–1.01) for dual use vs. smoking
only, and 0.85 (0.68–1.05) for the interaction, with no evidence
of between-study heterogeneity. Results for ever use for IHD,
CHD or AMI, and results for stroke and for all CVD are less numer-
ous, but similarly do not suggest any effect of dual use.
Table 3 summarizes results for cancer. Here, most of the results
relate to ever tobacco use. Of the ﬁfteen interaction estimates
shown, four are non-signiﬁcantly above 1.0, two equal to 1.0, and
nine less than 1.0, signiﬁcantly (p < 0.05) so in ﬁve cases. The sig-
niﬁcant negative interactions for squamous cell oesophageal can-
cer and for non-cardia stomach cancer seen in the construction
workers study (Zendehdel et al., 2008) arise from signiﬁcant in-
creases associated with snus being seen in never smokers but not
in ever smokers. As noted elsewhere (Lee, 2011), the overall evi-
dence on effects of snus suggests no relationship with stomach
cancer and at most suggestive evidence of a possible effect on
oesophageal cancer. The negative interactions for smoking-related
cancer and for mortality from any cancer (Roosaar et al., 2008) and
on time from diagnosis to death from cancer of the same primary
site (Nordenvall et al., 2013) again arise from increases associated
with snus seen in never smokers that are not seen in smokers.
Table 3 also includes results for respiratory mortality, for total
non-cancer mortality, and for overall cancer, which also show no
evidence of a positive interaction.
Table 1
Study details for publications providing relevant evidence on health effects.
Reference Source
table
Study
design
(size)a
Timingb Sexc Age (years) Data
on
ST
used
End pointe
Huhtasaari et al.
(1992)
I CCP (585) 1989–1991 M 35–64 C AMI
Persson et al. (1993) 1, 2 CCP
(63,82)f
1984–1997 M 15–79 E CD, UC
Schildt et al. (1998) III CCP (410) 1980–1989 M, F Mean 69.6 (M) mean 72.3
(F)
C, E Oral cancer
Huhtasaari et al.
(1999)
1 CCP (687) 1991–1993 M 25–64 C AMI
Ye et al. (1999) VII CCP (375) 1989–1995 M,F 40–79 E Gastric cancer
Hergens et al. (2005) 3 CCP (1432) 1992–1994 M 45–70 C, E AMI
Johansson et al.
(2005)
3 PC (3120) 1988–1989, 12 years M 30–74 C CHD
Haglund et al. (2007) III, IV PC (5002) 1988–1989, 14–16 years M 16–74 C IHD, stroke
Wennberg et al.
(2007)
2,3 NCC (525) 1985–1999 M 30–74 C AMI
Roosaar et al. (2008) II PC (9976) 1973–1974, 28–29 years M 15+ E All cancer, oral cancer, all deaths, respiratory
deaths
Zendehdel et al.
(2008)
III, IV PC
(336381)
1971–1993, mean
22.2 years
M Mean 34.7 E Gastroesophageal cancer
Hansson et al. (2009) 2 PC (16642) 1998–2002, 4.9 years M 40+ C, E CVD, IHD, stroke
Hedström et al.
(2009)
4 CCP (902) 2005–2008 M, F 16–70 E MS
Aro et al. (2010) 2–6 CS (1001)g 1998–2001 M, F 18–80 C, E Gastrointestinal morbidity
Carlens et al. (2010) 4 PC
(277777)
1978–1993, mean
20 years
M Mean 36 E RA, UC, CD, sarcoidosis, MS
Wikström et al.
(2010)c
1 CS
(605203)h
1999–2006 F Child bearing age C GH, pre-eclampsia
Wikström et al.
(2010)b
1 CS
(610879)h
1999–2006 F Child bearing age C Still births, complications of pregnancy
Wikström et al.
(2010)a
2 CS
(610199)h
1999–2006 F Child bearing age C Preterm birth
Gunnerbeck et al.
(2011)
1 CS
(609551)h
1999–2006 F Child bearing age C Preterm birth, SGA, neonatal apnea
Nordenvall et al.
(2011)
2 PC
(336381)
1971–1992, mean
24 years
M Mean 35 E Colon cancer, rectal cancer, anal cancer
Nordenvall et al.
(2013)
2 PC (40230)i 1971–1992, To 2007i M Mean 67 at cancer
diagnosis
E Cancer, other causes
a CCP = case-control study with population controls, CS = cross-sectional study, NCC = nested case-control study, PC = prospective cohort study. Numbers in brackets are of
cases for case-control study, of at risk for prospective cohort studies, and of subjects for the cross-sectional study.
b The timing of the initial interviews is given, and then the length of follow-up for prospective cohort studies.
c F = female, M = male.
d C = data available for current use, E = data available for ever use.
e AMI = acute myocardial infarction, CD = Crohn’s disease, CHD = coronary heart disease, CVD = cardiovascular disease, GH = gestational hypertension, IHD = ischaemic
heart disease, MS = multiple sclerosis, RA = rheumatoid arthritis, SGA = small for gestational age, UC = ulcerative colitis.
f 63 Cases of Crohn’s disease, 82 of ulcerative colitis.
g The 1001 subjects underwent an oesophagogastroduodenoscopy.
h Births.
i The study concerned survival of 40,230 men with incident cancer among 33,6381 workers interviewed initially in 1971–1992.
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nancy and birth from a series of papers (Gunnerbeck et al., 2011;
Wikström et al., 2010a,b,c) based on the Swedish Medical Register.
For three conditions (pre-eclampsia, diabetes, antenatal bleeding)
there is no evidence of an effect of snus use, in either exsmokers
or smokers, or of an interaction. For ﬁve conditions (very preterm
birth, preterm birth, still births, small for gestational age, neonatal
apnea), there is a signiﬁcant (p < 0.05) association with snus use in
non-smokers, but not in smokers, and the interaction is non-signif-
icantly negative. The only condition showing a signiﬁcant positive
interaction is gestational hypertension, where an association with
snus use is evident in smokers, but not in non-smokers.
Table 5 summarizes results for chronic inﬂammatory diseases.
There is no consistent evidence of an effect of snus on any of the
ﬁve diseases considered in either never or ever smokers, and nosigniﬁcant positive interaction. A signiﬁcant (p < 0.05) negative
interaction for multiple sclerosis seen in one study (Carlens et al.,
2010), due to an increased risk in never smokers but not in ever
smokers, was not seen in the other study with relevant data
(Hedström et al., 2009).
One further study (Aro et al., 2010) presented detailed results
for gastrointestinal morbidity, allowing calculation of interactions,
both for ever/never use and for current/noncurrent use, for a range
of endpoints, including reﬂux symptoms, dyspepsia, irritable bo-
wel syndrome, epigastric pain, abdominal pain, oesophagitis, and
Helicobacter pylori infection. Of eighteen interactions calculated
(details not shown), eight were greater than 1.0 and 10 less, with
only one signiﬁcant at p < 0.05. This was for irritable bowel syn-
drome, where an association with current snus use was evident
in current smokers (OR 2.90, 95% CI 1.10–7.62) but not in
Table 2
Dual use and cardiovascular disease.a
Disease Source Current or ever
use
Cases in dual
users
RR/OR (95% CI) Snus only vs.
neither
Dual users vs. smoking
only
Interactionb
IHD, CHD or AMI
IHD incidence Hansson et al. (2009) Ever 101 0.92 (0.61–1.39) 0.95 (0.74–1.22) 1.03 (0.64–1.67)
AMI casesc Hergens et al. (2005) Ever 203 0.87 (0.48–1.55) 0.99 (0.80–1.22) 1.14 (0.62–2.13)d
IHD incidence Haglund et al. (2007) Current 15 0.77 (0.51–1.15) 0.94 (0.56–1.59) 1.22 (0.63–2.37)e
IHD incidence Hansson et al. (2009) Current 9 0.90 (0.67–1.21) 0.75 (0.36–1.55) 0.83 (0.38–1.82)
AMI casesc Hergens et al. (2005) Current 66 1.21 (0.89–1.63) 0.80 (0.55–1.16) 0.66 (0.41–1.07)f
AMI casesc Huhtasaari et al.
(1992)
Current 32 0.79 (0.54–1.13) 0.68 (0.40–1.17) 0.87 (0.45–1.67)g
AMI casesc Huhtasaari et al.
(1999)
Current 20 0.96 (0.65–1.41) 0.73 (0.34–1.57) 0.76 (0.32–1.80)
CHD incidence Johansson et al.
(2005)
Current 10h 0.99 (0.63–1.56) 1.19 (0.60–2.37) 1.20 (0.52–2.73)
AMI casesc Wennberg et al.
(2007)
Current 30 1.00 (0.71–1.43) 0.82 (0.48–1.40) 0.82 (0.43–1.55)i
Totalj 7 Studies Current 182 0.95 (0.83–1.09) 0.82 (0.67–1.01) 0.85 (0.68–1.05)
Stroke
Stroke
incidence
Hansson et al. (2009) Ever 43 1.24 (0.78–1.97) 0.83 (0.59–1.16) 0.67 (0.38–1.19)
Stroke casesc Haglund et al. (2007) Current 9 1.07 (0.65–1.77) 1.41 (0.71–2.83) 1.32 (0.56–3.11)k
Stroke
incidence
Hansson et al. (2009) Current 5 0.89 (0.61–1.31) 0.90 (0.36–2.27) 1.01 (0.37–2.73)
All CVD
CVD incidence Hansson et al. (2009) Ever 138 1.07 (0.79–1.45) 0.91 (0.75–1.11) 0.85 (0.59–1.22)
CVD incidence Hansson et al. (2009) Current 14 0.93 (0.74–1.17) 0.81 (0.46–1.43) 0.87 (0.47–1.60)
a All RR/OR estimates are for males. All estimates are adjusted for age and other risk factors except for two studies Huhtasaari et al. (1992, 1999), where the estimates are
unadjusted.
b Ratio of RR/OR for dual users vs. smoking only to RR/OR for snus only vs. neither.
c Fatal and non-fatal cases.
d Interaction 1.24 (0.62–2.46) for non-fatal AMI and 0.50 (0.16–1.58) for fatal AMI.
e Interaction 0.74 (0.19–2.97) for IHD mortality.
f Interaction 0.60 (0.36–0.99) for non-fatal AMI and 0.89 (0.36–2.18) for fatal AMI.
g Interaction 0.82 (0.34–1.98) for age 35–54 and 0.70 (0.23–2.10) for age 55–64.
h Estimated.
i Interaction 0.25 (0.06–1.03) for fatal AMI in 28 days and 0.16 (0.03–0.89) for sudden cardiac death with survival less than 24 h.
j Results of ﬁxed-effects meta-analysis are shown, there being no signiﬁcant heterogeneity between studies.
k Interaction 4.17 (0.78–22.36) for stroke mortality.
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as 3.89 (1.28–11.86). This interaction was not seen (0.76, 0.35–
1.66) in analyses based on ever/never use.
3.2. Consumption of cigarettes and snus in single and dual users
Table 6 presents 12 comparisons from 10 studies of cigarette
consumption in dual users and in those who smoke but do not
use snus. All show reduced cigarette consumption in dual users,
the mean ratio being 0.74 (SE 0.15). Table 6 also presents six com-
parisons of snus use in dual users and in those who use snus but do
not smoke. With the exception of one small study of military con-
scripts, all show reduced snus use in dual users, the mean ratio
being 0.80 (SE 0.15).
Two of those studies also compared cotinine levels, as a marker
of total nicotine uptake, in dual users and single users. In one study
(Eliasson et al., 1995), mean plasma cotinine levels in dual users,
308 ng/ml, were higher than in those who only smoked, 242 ng/
ml, but lower than in those who only used snus, 351 ng/ml
(p < 0.01 for difference between groups). In the other (Wennmalm
et al., 1991) a different pattern was seen, with median urinary coti-
nine higher in dual users, 1773 ng/ml, than in either those who
only smoked, 1560 ng/ml, or those who only used snus, 1210 ng/
ml (no signiﬁcant difference between groups).
3.3. Frequency of dual use and the interrelationship of snus use and
smoking
Table 7 presents data from selected recent surveys on current
smoking and current snus use. Based on these data, and from moreextensive data in Table 5 of the earlier review (Lee, 2011), it can be
seen that in Swedish adults, the prevalence of dual use is quite low,
with rates reducing with age, and lower in women than men. It is
also evident that there is no strong association between snus use
and smoking. In Norwegian adults, the prevalence of dual use is
lower still, and smokers are less likely to use snus than are non-
smokers. In Swedish adolescents, however, the prevalence of dual
use may be higher, though dependent on the deﬁnitions used,
and there is a consistent tendency for smokers to be much more
likely than non-smokers to use snus. Odds ratios ranging from
about 4 to 15 can be estimated from many other Swedish studies
of adolescents (Lee, 2011).
For ever smoking and ever snus use, the situation is rather dif-
ferent. Table 8 presents data from the VIP survey (Norberg et al.,
2011), and, based on this and additional data given in Table 6 of
the earlier review (Lee, 2011), it can be seen that the frequency
of dual ever use is much higher than the frequency of dual current
use. Also, those who have ever smoked are much more likely than
those who have never smoked to have ever used snus, a tendency
which is even more strongly seen in adolescents.
The observations of a much higher prevalence of dual use and a
much stronger association between the habits, when estimated
based on ever use rather than current use, is consistent with some
people avoiding tobacco, and many of the rest trying both prod-
ucts, eventually settling for one.
3.4. Does snus use affect initiation of smoking?
Though evidence is somewhat limited, dual users are clearly
more likely to have started on cigarettes than have started on snus.
Table 3
Dual use and cancer, respiratory and all cause mortality.a
Disease Source Cases in dual
users
RR/OR (95% CI) Snus only vs.
neither
Dual users vs. smoking
only
Interactionb
Oral cancer – squamous cell Schildt et al. (1998) 10 0.86 (0.51–1.44) 0.40 (0.17–0.93) 0.47 (0.17–1.26)
Oral cancer – squamous cell Schildt et al. (1998) 39 1.20 (0.67–2.15) 0.73 (0.45–1.19) 0.61 (0.29–1.30)
Oropharyngeal cancer Roosaar et al. (2008) 6 2.30 (0.70–8.30) 3.66 (1.45–9.24) 1.59 (0.34–7.46)
Oesophageal cancer –
adenocarcinoma
Zendehdel et al.
(2008)
26 0.20 (0.02–1.90) 1.00 (0.60–1.50) 5.00 (0.50–49.74)
Oesophageal cancer – squamous
cell
Zendehdel et al.
(2008)
40 3.50 (1.60–7.60) 0.80 (0.60–1.20) 0.23 (0.10–0.54)
Gastric cancer Ye et al. (1999) 72 0.50 (0.20–1.22) 0.80 (0.57–1.13) 1.60 (0.61–4.18)
Stomach cancer – cardia Zendehdel et al.
(2008)
50 0.90 (0.40–2.20) 0.90 (0.70–1.30) 1.00 (0.42–1.37)
Stomach cancer – non cardia Zendehdel et al.
(2008)
185 1.40 (1.10–1.90) 1.00 (0.90–1.20) 0.71 (0.52–0.97)
Colon cancerc Nordenvall et al.
(2011)
440 1.08 (0.91–1.29) 1.08 (0.97–1.21) 1.00 (0.82–1.24)
Rectal cancer Nordenvall et al.
(2011)
319 1.05 (0.85–1.31) 1.04 (0.92–1.19) 0.99 (0.77–1.28)
Anal cancer Nordenvall et al.
(2011)
14 0.61 (0.07–5.07) 1.44 (0.74–2.81) 2.37 (0.25–22.28)
Smoking-related cancer –
incidenced
Roosaar et al. (2008) 32 1.60 (1.10–2.50) 0.79 (0.54–1.16) 0.50 (0.28–0.87)
Any cancer – incidence Roosaar et al. (2008) 99 1.10 (0.90–1.40) 0.94 (0.78–1.12) 0.85 (0.64–1.13)
Any cancer – mortality Roosaar et al. (2008) NAe 1.28 (0.96–1.69) 0.80 (0.62–1.04) 0.63 (0.43–0.92)
Any cancer – survivalf Nordenvall et al.
(2013)
2122 1.15 (1.05–1.26) 0.94 (0.89–0.99) 0.82 (0.74–0.91)
Respiratory mortality – age <80 Roosaar et al. (2008) NAe 0.80 (0.20–3.00) 0.80 (0.36–1.79) 1.00 (0.21–4.84)
Respiratory mortality – age 80+ Roosaar et al. (2008) NAe 2.00 (1.20–3.40) 1.53 (0.86–2.92) 0.77 (0.33–1.75)
Non-cancer mortalityg Nordenvall et al.
(2013)
1579 1.12 (1.01–1.25) 1.02 (0.97–1.08) 0.91 (0.81–1.03)
Any cause – survivalh Nordenvall et al.
(2013)
3859 1.13 (1.05–1.20) 0.97 (0.93–1.00) 0.86 (0.79–0.92)
Total mortality Roosaar et al. (2008) NAe 1.23 (1.09–1.40) 0.97 (0.85–1.11) 0.79 (0.66–0.95)
a All RR/OR estimates are for males, and are for ever use, except for one study Schildt et al. (1998), where the estimates are for sexes combined and current use. All
estimates are adjusted for age and other risk factors.
b Ratio of RR/OR for dual users vs. smoking only to RR/OR for snus only vs. neither.
c Interactions 1.18 (0.86–1.63) for cancer of right colon and 0.91 (0.65–1.27) for cancer of left colon.
d As deﬁned by Levitz et al. (2004); it includes oral, pharyngeal, oesophageal, gastric, pancreatic, laryngeal and pulmonary cancer as well as cancer of the kidney, bladder
and other urinary organs.
e NA = not available.
f Death from cancer at the same site as the primary cancer – analysis is based on follow-up of incident cancer cases.
g Death from causes other than cancer or from cancer of a site other than the primary cancer – analysis is based on follow-up of incident cancer cases.
h Analysis is based on follow-up of incident cancer cases.
Table 4
Dual use and conditions related to pregnancy and birth.a
Disease Source Cases in dual users RR/OR 95% CI Snus only vs. neither Dual users vs. smoking only Interactionb
Very preterm birth Wikström et al. (2010a) 4 1.34 (1.03–1.74) 0.84 (0.31–2.23) 0.63 (0.23–1.72)
Preterm birth Wikström et al. (2010a) 24 1.24 (1.12–1.37) 0.94 (0.64–1.40) 0.76 (0.51–1.14)
Pre-eclampsia Wikström et al. (2010c) 13 1.11 (0.97–1.28) 1.20 (0.65–2.20) 1.08 (0.58–2.01)
Gestational hypertension Wikström et al. (2010c) 7 0.89 (0.68–1.15) 2.72 (1.30–5.69) 3.06 (1.40–6.69)
Still births Wikström et al. (2010b) 4 1.91 (1.40–2.62) 1.67 (0.62–4.49) 0.87 (0.31–2.47)
Diabetes Wikström et al. (2010b) 7 0.93 (0.76–1.14) 0.88 (0.42–0.84) 0.95 (0.44–2.04)
Antenatal bleeding Wikström et al. (2010b) 5 1.21 (0.98–1.48) 0.66 (0.27–1.58) 0.55 (0.22–1.34)
Small for gestational age Wikström et al. (2010b) 23 1.18 (1.01–1.38) 1.12 (0.75–1.67) 0.95 (0.62–1.46)
Neonatal apnea Gunnerbeck et al. (2011) 0 1.96 (1.30–2.96) 0.00 0.00
a RR/ORs for pre-eclampsia, gestational hypertension, stillbirths and neonatal apnea are adjusted for age and other characteristics. Others are unadjusted and are calculated
based on rates (%) to 1 decimal place, so are subject to some inaccuracy. All estimates are for current use.
b Ratio of RR/OR for dual users vs. smoking only to RR/OR for snus only vs. neither.
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(Furberg et al., 2005), 2422 (89.3%) started on cigarettes as against
291 (10.7%) starting on snus, while in the Your Country and Your
Life study in Stockholm (Ramström and Foulds, 2006) 338
(77.2%) started on cigarettes as against 100 (22.8%) starting on
snus. The percentage starting on snus is likely to increase as the
acceptability of snus among adolescents has increased. This may
explain why, in a recent analysis of six surveys in Norway (Lund
and McNeill, 2013) the proportion of men with a history of dualuse who started on snus increased steadily with decreasing age,
from 3.9% for age 45+ years, through 25.9% for age 25–44 years,
to 42.3% for age 15–24 years. (Note that all the above estimates ex-
clude the small proportion of dual users where the time of start of
both products was the same.)
A number of cohort studies have presented data in which never
smokers or non-smokers have been followed up, and the probabil-
ity of smoking at the end of follow-up can be related to snus use at
baseline. The largest study to present such data is the VIP study,
Table 5
Dual use and chronic inﬂammatory disease.a
Disease Source Cases in dual users RR/OR 95% CI Snus only vs. neither Dual users vs. smoking only Interactionb
Rheumatoid arthritis Carlens et al. (2010) 141 1.20 (0.80–1.80) 0.87 (0.71–1.06) 0.72 (0.46–1.14)
Sarcoidosis Carlens et al. (2010) 41 1.10 (0.80–1.50) 1.00 (0.70–1.42) 0.91 (0.57–1.46)
Ulcerative colitis Carlens et al. (2010) 191 1.00 (0.80–1.20) 1.17 (0.98–1.39) 1.17 (0.89–1.52)
Ulcerative colitis Persson et al. (1993) 15 1.10 (0.40–3.10) 3.25 (1.23–8.56) 2.95 (0.72–12.09)
Crohn’s disease Carlens et al. (2010) 108 1.00 (0.80–1.40) 0.93 (0.75–1.16) 0.93 (0.65–1.33)
Crohn’s disease Persson et al. (1993) 11 0.90 (0.30–3.10) 2.65 (0.94–7.47) 2.94 (0.62–14.02)
Multiple sclerosis Carlens et al. (2010) 37 1.80 (1.10–2.90) 0.76 (0.51–1.12) 0.42 (0.23–0.79)
Multiple sclerosis Hedström et al. (2009) 87 0.40 (0.03–5.34) 0.40 (0.19–0.82) 1.00 (0.07–13.34)
a All RR/OR estimates are for males, and for ever use, except for one study Hedström et al. (2009) where they are for sexes combined, and snus use is current/non-current.
All estimates are adjusted at least for age.
b Ratio of RR/OR for dual users vs. smoking only to RR/OR for snus only vs. neither.
Table 6
Consumption of cigarettes and snus in single and dual users.a
Source Sex Age
(yrs)
Year No. of dual
users
Current or ever
use
Cigarettes per day Snus use
Smoking
only
Dual use Snus only Dual use Units
Aro et al. (2010) M+F 20+ 1998–
2001
22 C 11.5 6.2 3.2 2.2 cans/
wk
Carlens et al. (2010)b M Mean
36
1978–
1993
43,425 E 12 9 22 16 g/day
Eliasson et al. (1995) M 25–64 1990 38 C 16.5 (0.6) 10.1 (1.1) 3.2 (0.2) 2.5 (0.2) cans/
wk
Gilljam and Galanti
(2003)
M 25–55 2000 84 C 15.1 (0.5) 11.0 (1.1)
F 25–55 2000 14 C 12.3 (0.3) 11.7 (3.1)
Hansson et al. (2009) M 20+ 1998–
2002
1647 Cc 16.7 16.5
Hergens et al. (2005) M 45–70 1992–
1994
60 Cd 18.6 16.4
Janzon and Hedblad
(2009)
M 45–73 1991–
1996
250 C 16.1 (0.2) 12.3 (0.6)
F 45–73 1991–
1996
21 C 12.9 (0.1) 7.8 (0.7)
Lund and McNeill (2013) M 16–74 2005–
2010
226 C 11.5 (0.3) 8.1 (0.5)
Rodu et al. (2002) M 25–64 1986–
1999
NA C 15.8 10.8 0.42 0.25 cans/
wk
Sundbeck et al. (2009) M 30–75 2001–
2003
116 Ce 3.7 3.4 cans/
wk
Wennmalm et al. (1991) M 18–19 Unknown 30 C 12.2 (0.8) 7.8 (1.3) 25 (1) 27 (3) g/day
a Standard errors are given in brackets, where available.
b The source also presents data showing that dual users have consistently lower cigarette consumption and snus use than do single users in each of ﬁve age groups (<24,
25–34, 35–44, 45–54 and 55+ years).
c Current snus use; ever smoking.
d Among former smokers, consumption was 20.6 cigs/day in non-snus users and 18.4 cigs/day in snus users.
e Current snus use; former smoking.
130 P.N. Lee / Regulatory Toxicology and Pharmacology 69 (2014) 125–134which has recently reported results of 10-year follow-up from
baseline during 1990 to 1997 (Norberg et al., 2011). In both sexes,
the probability of initiation during follow-up was signiﬁcantly
(p < 0.05) higher for those using snus at baseline users than for
those not using snus (males 6.1% vs. 2.6%, RR 2.35 95%, CI 1.89–
2.92; females 8.1% vs. 3.2%, RR 2.53, CI 1.76–3.63). An increased
probability is also consistently seen in other studies (Lee, 2011).
Interpretation of this association is hindered by the minimal
adjustment for factors predictive of initiation, one study (Haukkala
et al., 2006) reporting that adjustment for school, sport participa-
tion, and school achievement substantially reduced the
association.
Two studies of Swedish adults (Furberg et al., 2005; Ramström
and Foulds, 2006) used retrospective data to study effects on initi-
ation, both reporting that the percentage initiating smoking among
those who started on snus was substantially lower than among
those who had not started on snus. However, as demonstrated ear-
lier (Lee, 2011), these analyses may be considerably biased by thetime available for initiation not being controlled for in the analysis.
For a given follow-up period, those starting on snus can only initi-
ate smoking from that time point, but those not starting on snus
can initiate smoking from the start of the period.
There is thus little reliable information on snus use and initia-
tion. The RRs in the analyses of the cohort data are biased upward
by lack of confounder control, while the retrospective analyses are
biased downwards.
3.5. Does snus use affect cessation of smoking?
A number of cohort studies have presented data in which smok-
ers have been followed up, and the probability of quitting at the
end of follow-up can be related to snus use at baseline. As for ini-
tiation, the VIP study presents the most comprehensive data. Re-
cent results (Norberg et al., 2011) show that, in both sexes, the
probability of quitting is higher for dual users at baseline than
for those who only smoked (males 57.3% vs. 41.5%, RR 1.38, 95%
Table 7
Current smoking and current snus use – selected recent data for Sweden (or other Nordic countries).a
Source Year Age (years) Sex Nb Frequency (%) OR (95% CI)
Dual Snusc Smokingc Neither
Studies in adults
VIP surveyd 2002–2007 40 M 6055 5.6 28.1 7.1 59.1 1.66 (1.42–1.93)
50 M 6348 5.9 23.8 11.3 58.9 1.29 (1.13–1.48)
60 M 6413 3.5 17.5 13.1 66.0 1.01 (0.86–1.18)
40 F 6286 2.1 11.8 12.2 74.0 1.08 (0.88–1.32)
50 F 6698 2.0 6.2 19.4 72.3 1.20 (0.98–1.47)
60 F 6610 0.6 2.5 18.2 78.7 1.04 (0.73–1.48)
Skåne public health surveye 2004 18–80 M 11,855 3.8 15.7 15.3 65.2 1.03 (0.92–1.16)
18–80 F 14,050 0.5 1.8 21.8 75.9 1.01 (0.78–1.32)
SIRUS Norwayf 2006 21–30 M 1198 1.5 15.3 16.4 66.8 0.40 (0.24–0.67)
Stockholm public health surveyg 2006 18+ M 15,428 2.4 17.0 11.3 69.3 0.86 (0.76–0.97)
18+ F 18,761 0.5 3.1 15.2 81.2 0.88 (0.71–1.10)
SSB Norwayh 2008/2009 16–74 M 4444 0.9 9.9 20.0 69.1 0.31 (0.23–0.44)
16–74 F 4592 0.1 1.3 20.2 78.4 0.30 (0.12–0.77)
SSLC surveyi 2008–2011 16–34 M 1729 4.3 35.6 15.9 0.8 0.95 (0.72–1.24)
35–54 M 1631 5.6 42.8 21.9 1.2 0.78 (0.61–1.00)
55–64 M 1760 2.4 28.8 29.7 1.1 0.42 (0.30–0.58)
75+ M 1128 0.5 8.0 7.0 0.4 1.12 (0.47–2.67)
16–34 F 1711 0.8 7.2 25.0 0.9 0.63 (0.35–1.13)
35–54 F 1848 0.8 8.0 32.9 0.8 0.47 (0.27–0.81)
55+ F 3212 0.3 1.8 25.4 0.2 0.92 (0.44–1.93)
Health on equal terms surveyj 2009–2012 16–29 M 2554 1.8 17.4 6.8 74.1 1.10 (0.78–1.56)
30–44 M 3524 1.8 20.4 7.0 70.7 0.91 (0.68–1.21)
45–64 M 6491 3.0 17.8 12.3 66.9 0.92 (0.77–1.09)
65–84 M 5246 1.2 10.0 9.0 79.8 1.09 (0.83–1.43)
16–29 F 3465 0.4 4.5 11.3 83.8 0.71 (0.41–1.22)
30–44 F 4748 0.5 4.2 9.8 85.6 1.05 (0.68–1.63)
45–64 F 7621 0.5 3.0 16.9 79.6 0.74 (0.52–1.05)
65–84 F 5559 0.3 1.4 10.7 87.6 1.67 (0.96–2.90)
Studies in adolescents
Postal surveysk 2003 13,15,17 M 1398 3.0 6.0 3.0 88.0 14.6 (9.05–23.7)
Norway telephone surveyl 2004, 2007 16–20 M 2441 5.9 15.7 12.6 65.8 1.96 (1.56–2.46)
16–20 F 2374 1.4 3.5 18.4 76.7 1.73 (1.15–2.62)
Norway school surveym 2005 15–16 M 809 2.5 5.4 6.1 86.0 6.53 (3.58–11.9)
Finnish adolescentsn 2005–2011 14 M 3360 0.1 0.3 6.0 93.6 7.02 (2.30–21.5)
16 M 2739 0.8 1.3 20.5 77.4 2.22 (1.29–3.83)
18 M 2190 1.0 1.8 28.7 68.6 1.34 (0.78–2.28)
Norway telephone surveyo 2006 15–18 M 2896 12.7 25.6 7.6 54.2 3.56 (2.94–4.29)
CAN school surveysp 2009–2012 15–16 M 9578 1.0 4.6 4.8 89.6 4.02 (3.16–5.11)
17–18 M 7513 1.5 12.0 7.0 79.5 1.38 (1.11–1.71)
15–16 F 9615 0.1 0.3 7.3 92.3 7.45 (3.86–14.4)
17–18 F 7446 0.3 1.7 12.7 85.3 1.20 (0.76–1.89)
a Except where stated, surveys are national and are in Sweden.
b Number of subjects. Where annual or bi-annual data are available, results shown are pooled from the four most recent surveys.
c Only the stated habit.
d VIP = västerbotten intervention program. Current snus = regular, current smoking = daily or intermittent. Source : Norberg et al. (2011).
e Postal survey conducted in Skåne County. Current snus = daily, current smoking = daily or intermittent. Source: Lindström (2007).
f SIRUS = statens institutt for rusmiddelforskning (Norwegian institute for alcohol and drug research). Drug use among young adults survey (Rusmiddelbruk blant unge
voksne). Source: Lund et al. (2007).
g Deﬁnitions of smoking and snus are for daily use. Source: Engström et al. (2010).
h SSB = statistisk sentralbyrå (statistics Norway). Deﬁnitions of smoking and snus are for daily use. Source: Helleve et al. (2010).
i SSLC = Swedish survey of living conditions (Undersknigar on levnadsförhållanden, ULF). Deﬁnitions of smoking and snus are for daily use. Source: Statistiska Centralbyrån
(SCB Statistics Sweden) (2013).
j Deﬁnitions of smoking and snus are for daily use. Source: Statens Folkhalsoinstitut (Swedish National Institute of Public Health) (2012).
k Deﬁnitions of smoking and snus include regular and occasional use. Source: Nilsson et al. (2009).
l Deﬁnitions of smoking and snus include daily or weekly use. Source: Øverland et al. (2010).
m Deﬁnitions of smoking and snus are for daily use. Source: Aaro et al. (2008).
n Survey conducted in alternate years. Deﬁnitions of smoking and snus are for daily use. Source: Raisamo et al. (2011).
o Survey conducted in 11 of 19 Norwegian counties with high prevalence of snus use. Deﬁnitions of smoking and snus include daily or weekly use. Source: Larsen et al.
(2013).
p CAN = central alliance for alcohol and drug information. Deﬁnitions of smoking and snus are for daily use. Source: Liefman (2013).
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This increased probability is consistent with data presented in Ta-
ble 8 of the earlier review (Lee, 2011), though the data generally
suffer from lack of adjustment for any potential confounding vari-
ables. However, results from a telephone helpline cohort (Helgason
et al., 2004) showed that adjustment for age, sex and factors
related to smoking abstention did not modify the association
between snus use and quitting.Consistent with the results of the cohort studies are ﬁndings
from an analysis of seven Norwegian cross-sectional studies (Lund
et al., 2011) which reported a consistent tendency for the quit ratio
(the proportion of ever smokers who have quit) to be higher in
those who were snus users at the time of interview, as compared
to those who had never used snus. However, apart from being
unadjusted for sex, age, or any factor possibly related to quitting,
the analysis does not fully take into account the time sequence
Table 8
Ever smoking and ever snus use – data from the VIP survey for 2002 to 2007 Norberg et al. (2011)a.
Sex Age (yrs) Nc Frequency of ever useb OR (95% CI)
Dual Snusd Smokingd Neither
Males 40 6055 24.6 22.4 8.7 44.2 5.58 (4.95–6.28)
50 6348 34.2 14.2 17.5 34.0 4.68 (4.21–5.70)
60 6413 32.2 6.5 29.8 31.6 5.25 (4.65–5.94)
Females 40 6286 15.9 6.2 25.2 52.8 5.37 (4.71–6.13)
50 6698 11.5 1.1 46.0 41.3 9.39 (7.35–12.0)
60 6610 4.1 0.2 50.4 45.3 18.4 (10.6–32.1)
a VIP = Västerbotten Intervention Program.
b Daily or intermittent.
c N = Number of subjects.
d Only ever used.
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quit smoking may actually have not used snus until after they
had quit.
A number of publications (Furberg et al., 2005, 2008; Gilljam
and Galanti, 2003; Ramström and Foulds, 2006) have presented
analyses of retrospective studies which consistently show snus
use is associated with increased quitting. However, as discussed
earlier (Lee, 2011), these analyses are biased. This is partly because
snus users may include some people who started snus use after
quitting, and partly because the time available for quitting has
not properly been controlled for. These biases, however, seem un-
likely to explain the association, and generally all the evidence
seems consistent with snus use facilitating quitting, though subject
to limitations.
Randomized controlled trials avoid issues of bias. Two placebo-
controlled trials of snus as a quitting aid have been conducted, one
in the USA (Fagerström et al., 2011) and one in Serbia (Joksic´ et al.,
2011). A meta-analysis based on the combined results (Rutqvist
et al., 2013) recently reported a relative success rate of 2.83 (95%
CI 1.03–7.75) of borderline signiﬁcance for the primary outcome,
which was biologically conﬁrmed cessation over a 6-month period.
These results conﬁrm the conclusions drawn from the epidemio-
logical studies.4. Discussion
The possibility of any special risk associated with dual use of
snus and smoking has been investigated by testing whether the
RR/OR associated with snus use in smokers exceeds that seen in
non-smokers, i.e. whether there is any signiﬁcant interaction (on
a multiplicative scale). As can be seen from Tables 2–5, the avail-
able data on speciﬁc diseases are generally quite limited, except
perhaps for IHD/CHD/AMI. Overall, however, there seems little evi-
dence of any special risk from dual use, consistent with the ﬁnd-
ings of a review (Frost-Pineda et al., 2010) on dual use of
smokeless tobacco and smoking, which also considered evidence
from US studies . Of the 51 RR/OR estimates with 95% CIs shown
in the main body of these tables, a signiﬁcant (p < 0.05) positive
interaction was seen only for gestational hypertension (see Ta-
ble 5), and that may be a chance ﬁnding given the number of esti-
mates considered. In fact, there is some tendency for the
interaction estimates to show a less than expected risk in dual
users, with 32 of the 51 estimates below 1.0, 7 being signiﬁcantly
negative, as against only 15 above 1.0, with only that for gesta-
tional hypertension being signiﬁcantly positive. This may be be-
cause where variation in risk by tobacco habit is seen, it is much
more likely to be due to effects of smoking than to effects of snus,
and cigarette consumption in dual users is clearly lower than in
those who only smoke cigarettes, by an estimated 26% (SE 15%).It should be noted that the RRs in the tables comparing dual users
vs. smoking only are generally unadjusted for amount smoked.
Dual use can be deﬁned based on current use or on ever use, and
the tables make it clear which deﬁnition relates to which RR esti-
mate. RRs are more commonly available for current use for CVD,
and forever use for cancer, but there is no real indication of any
special hazard associated with dual use using either deﬁnition. It
should be noted, however, that the available data provide no infor-
mation on the duration of dual use. Long-term dual use may pro-
duce different risks than short-term dual use.
Also relevant is the fact that levels of tobacco-nitrosamines and
other toxicants in snus in Sweden have declined markedly over
time in relation to the implementation of the GothiaTek standard
for production and storage (Rutqvist et al., 2011). The fact that
many of our results relate to those who would have used snus in
earlier years adds reassurance that special hazards of dual use from
current products are unlikely.
In Sweden, the frequency of dual current use in adults is rela-
tively low, particularly in older populations, but the frequency of
dual ever use in adults, and the frequency of dual current use or
dual ever use in adolescents is much higher. This is consistent with
many tobacco users trying both products in adolescence, and tend-
ing later in life to settle for one or the other, given that they have
not quit both. For diseases such as cancer or vascular disease,
occurring mainly in older men and women, any special hazard
from dual use (if indeed it existed) would have little overall effect
on risk.
In older populations, dual users predominantly started tobacco
use with cigarettes, and where dual users end up using snus only, it
seems clear that they will be better off, health-wise, than if they
had continued smoking. In younger populations, a larger propor-
tion of dual users are starting on snus, and there is concern that
this might act as a ‘‘gateway’’ to cigarette smoking. It is unfortu-
nate that there is little reliable information on this. Retrospective
studies suggest that initiation of smoking is reduced by previous
snus use (Furberg et al., 2005, 2008; Gilljam and Galanti, 2003;
Ramström and Foulds, 2006) but the analyses may be markedly
biased by failure to control for the time available for initiation
(Lee, 2011). Also, cohort studies (e.g. Norberg et al., 2011) which
demonstrate a moderate tendency for previous snus use to be asso-
ciated with increased initiation of smoking are also biased, by fail-
ure to control adequately for factors associated with initiation. This
can be illustrated by a simple example in which a proportion of the
population would never take up tobacco, the probabilities of up-
take of smoking and of snus in the remainder being assumed to
be independent. In this situation, it is easy to show that, in the
whole population, if there is no control at all for factors associated
with initiation, there will be an apparent tendency for previous
snus use to be associated with initiation of smoking, despite this
assumed independence.
P.N. Lee / Regulatory Toxicology and Pharmacology 69 (2014) 125–134 133The evidence relating dual use to the subsequent probability of
quitting smoking is stronger, but still suffers from limitations due
to failure to control for relevant confounding variables, though any
biases seem less severe than for the evidence on quitting (Lee,
2011). Generally, the evidence consistently suggests that concom-
itant snus use is associated with an increased probability of quit-
ting, a conclusion that is supported by recent results from
randomized controlled trials (Rutqvist et al., 2013) using snus as
an aid to smoking cessation.
5. Conclusions
Evidence for a wide variety of health endpoints does not suggest
any special hazard associated with dual use of snus and smoking.
Of 51 interactions tested, only that for gestational hypertension
was signiﬁcantly (p < 0.05) positive, with the increase in risk asso-
ciated with snus use generally somewhat lower in smokers than in
non-smokers. In adults, the frequency of current dual use is quite
low, with dual users more likely to quit smoking than are smokers
who do not use snus.
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